JP2001213768A - Poultice - Google Patents
PoulticeInfo
- Publication number
- JP2001213768A JP2001213768A JP2000023766A JP2000023766A JP2001213768A JP 2001213768 A JP2001213768 A JP 2001213768A JP 2000023766 A JP2000023766 A JP 2000023766A JP 2000023766 A JP2000023766 A JP 2000023766A JP 2001213768 A JP2001213768 A JP 2001213768A
- Authority
- JP
- Japan
- Prior art keywords
- woven
- poultice
- thickness
- nonwoven fabric
- plaster
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、薄くて剥がれ難
く、使用感に優れたパップ剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a cataplasm which is thin and hard to peel off and which is excellent in usability.
【０００２】[0002]
【従来の技術】貼付剤には、親水性基剤を塗膏したパッ
プ剤と、疎水性基剤を塗膏したプラスター剤（テープ
剤）とがある。このうち、パップ剤は皮膚刺激性が弱く
皮膚にやさしいが、厚さがあり剥がれやすいので、使用
中の剥離を抑えるために、別の粘着シートを用いて上か
ら押さえたり、粘着力を強くすることが行われている。
しかし、粘着シートを用いた場合には簡便性が悪く、粘
着シートを皮膚から剥がす時に皮膚に損傷を与える。ま
た、パップ剤自体の粘着力を強くした場合にも、剥がす
際に、皮膚に損傷を与えてしまうという問題がある。パ
ップ剤を薄くすることにより、衣類との摩擦等による使
用時の剥離を抑えることができるが、薄型のパップ剤は
開発されていないのが現状である。2. Description of the Related Art Patches include cataplasms coated with a hydrophilic base and plasters (tapes) coated with a hydrophobic base. Of these, cataplasms have low skin irritation and are gentle on the skin, but because they are thick and easy to peel off, use another adhesive sheet to hold down from above or increase the adhesive strength to suppress peeling during use. That is being done.
However, when the adhesive sheet is used, the convenience is poor and the skin is damaged when the adhesive sheet is peeled off from the skin. Further, even when the adhesive strength of the poultice itself is increased, there is a problem that the skin is damaged when peeled off. By reducing the thickness of the poultice, peeling during use due to friction with clothing or the like can be suppressed, but a thin poultice has not been developed at present.
【０００３】パップ剤は、一般に、織布又は不織布に流
動性のあるパップ剤膏体を塗膏した後、これにライナー
フィルムを被覆して一定の大きさに裁断することにより
製造される。このとき、不織布に膏体が浸入した後に固
化することにより初めて支持体と膏体が一体化される。
しかし、膏体が織布又は不織布の塗膏面の反対側（裏
側）に達するまで浸入すると裏抜けを生じ、逆に織布又
は不織布への浸入が少ないと支持体と膏体が一体化され
ず、いずれも不良品となる。すなわち、パップ剤の製造
においては、膏体が織布又は不織布層の裏には抜けず、
適度な深度まで浸入することが重要で、逆の見方をすれ
ば、織布又は不織布は、膏体が裏に抜けない程度の厚み
が必要である（図１（１）参照）。従って、織布又は不
織布の厚さを薄くすることにより、パップ剤を薄くする
には限界があった。[0003] A cataplasm is generally produced by applying a fluid cataplasm to a woven or non-woven fabric, coating it with a liner film, and cutting it to a predetermined size. At this time, the support and the plaster are integrated only by solidifying after the plaster enters the nonwoven fabric.
However, if the plaster penetrates until it reaches the opposite side (back side) of the plaster surface of the woven or nonwoven fabric, strikethrough occurs, and if the penetration into the woven or nonwoven fabric is small, the support and the plaster are integrated. In each case, the products are defective. That is, in the production of cataplasm, the plaster does not come off the back of the woven or non-woven fabric layer,
It is important to penetrate to an appropriate depth, and from the opposite viewpoint, the woven or nonwoven fabric needs to have a thickness that does not allow the plaster to fall through (see FIG. 1 (1)). Therefore, there is a limit in reducing the thickness of the woven or nonwoven fabric to reduce the cataplasm.
【０００４】一方、パップ剤を薄くするには、塗膏する
膏体の量を少なくする方法も考えられる。しかし、塗膏
量を少なくすると、織布又は不織布中に膏体が埋没して
しまい、表面に均一な膏体面を構成できず、皮膚に貼付
することができなくなる。従って、従来のパップ剤は、
これらの欠点がでないような支持体の厚さと塗膏量に調
整して製造されている。On the other hand, in order to make the poultice thinner, a method of reducing the amount of plaster to be applied is also conceivable. However, when the amount of the plaster is reduced, the plaster is buried in the woven or non-woven fabric, so that a uniform plaster surface cannot be formed on the surface and it cannot be stuck to the skin. Therefore, conventional cataplasms are
It is manufactured by adjusting the thickness of the support and the amount of the plaster so as to avoid these disadvantages.
【０００５】これに対し、プラスター剤は薄く調製され
ているが、皮膚刺激性が強く、敏感な皮膚においてはか
ぶれ・発赤を生じる場合が多い等の問題がある。このた
め、使用時の簡便性及び使用感などから、皮膚刺激性の
ない薄型のパップ剤の開発が望まれている。[0005] On the other hand, although plaster preparations are prepared thinly, they have problems such as strong skin irritation and rash and redness on sensitive skin in many cases. For this reason, development of a thin cataplasm having no skin irritation has been desired in view of simplicity and feeling during use.
【０００６】また、貼付剤の臭いに関しては、パップ剤
及びプラスター剤のいずれにおいても、薬効成分やその
他の膏体成分が有する臭いのため、製剤にそれら特有の
臭いがある。このような臭いを抑えるため、香料を添加
したり、臭いのある薬効成分の配合量を減らすなどの対
策がなされているが、香料を添加した場合には皮膚刺激
性の影響があり、薬効成分の配合量を減らした場合に
は、十分な効果が得られないなどの問題が生じる。従っ
て、使用時に十分な効果が得られるとともに、使用して
いることを他人に知られないよう、臭いが抑えられた貼
付剤も望まれている。[0006] Regarding the odor of the patch, the preparation has a peculiar odor in both the cataplasm and the plaster because of the odor of the medicinal component and other plaster components. In order to suppress such odors, measures such as adding fragrances and reducing the amount of odorous medicinal ingredients have been taken, but adding fragrances has the effect of skin irritation, In the case where the blending amount of the compound is reduced, problems such as insufficient effects are caused. Therefore, there is a need for a patch that can provide a sufficient effect at the time of use and has a reduced odor so that others do not know that the patch is being used.
【０００７】[0007]
【発明が解決しようとする課題】従って、本発明の目的
は、薄くて剥がれ難く、また臭いが抑えられたパップ剤
を提供することにある。SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to provide a poultice which is thin, hard to peel off and has a low odor.
【０００８】[0008]
【課題を解決するための手段】本発明者らは、更に薄い
パップ剤を得るために鋭意研究を重ねた結果、織布又は
不織布と高分子フィルムとを積層させた支持体を用い、
この支持体のフィルムと織布又は不織布の接着面まで親
水性基剤を通過、浸入させることにより、支持体の厚さ
を限界まで薄くでき、薄くて剥がれ難いパップ剤が得ら
れること、また支持体の透湿度を調整することにより、
膏体成分の臭いが抑えられることを見出し、本発明を完
成した。Means for Solving the Problems The present inventors have conducted intensive studies to obtain a thinner cataplasm, and as a result, using a support in which a woven or nonwoven fabric and a polymer film are laminated,
By passing and infiltrating the hydrophilic base material to the adhesive surface between the film of the support and the woven or nonwoven fabric, the thickness of the support can be reduced to the limit, and a thin, hard-to-peel cataplasm can be obtained. By adjusting the moisture permeability of the body,
The present inventors have found that the smell of the plaster component can be suppressed and completed the present invention.
【０００９】すなわち、本発明は、高分子フィルムと織
布又は不織布とを積層した支持体の、織布又は不織布層
に親水性基剤が含浸され、かつ織布又は不織布表面に親
水性基剤面が形成され、厚さが１００〜１０００μmで
あるパップ剤を提供するものである。That is, according to the present invention, a hydrophilic substrate is impregnated in a woven or nonwoven layer of a support in which a polymer film and a woven or nonwoven fabric are laminated, and the hydrophilic substrate is impregnated on the surface of the woven or nonwoven fabric. The present invention provides a poultice having a surface formed and a thickness of 100 to 1000 μm.
【００１０】[0010]
【発明の実態の形態】本発明で用いられる支持体は、高
分子フィルムと織布又は不織布とを積層したものであ
る。ここで、高分子フィルムとしては、織布又は不織布
に含浸させた膏体の抜けを抑えられるものであれば特に
制限されず、例えばポリエチレン、ポリプロピレン、ポ
リエステル、ポリアミド、ポリビニルアルコール、ポリ
塩化ビニル、ポリ塩化ビニリデン、ポリウレタン、ポリ
スチレン、エチレン−酢酸ビニル共重合体、ポリカーボ
ネート、塩酸ゴム等で形成されたフィルムが挙げられ
る。高分子フィルムの硬さ、厚さ等はパップ剤の用途な
どにより、適宜選択することができるが、厚さは、０．
５〜１００μm、特に１〜５０μmが好ましい。DETAILED DESCRIPTION OF THE INVENTION The support used in the present invention is a laminate of a polymer film and a woven or nonwoven fabric. Here, the polymer film is not particularly limited as long as it can suppress the removal of the plaster impregnated in the woven or nonwoven fabric, and is, for example, polyethylene, polypropylene, polyester, polyamide, polyvinyl alcohol, polyvinyl chloride, or polyvinyl chloride. Examples include films formed of vinylidene chloride, polyurethane, polystyrene, ethylene-vinyl acetate copolymer, polycarbonate, hydrochloride rubber, and the like. The hardness, thickness, and the like of the polymer film can be appropriately selected depending on the use of the poultice, and the like.
It is preferably from 5 to 100 μm, particularly preferably from 1 to 50 μm.
【００１１】また、織布又は不織布としては、通常パッ
プ剤に使用されるものであれば特に制限されず、例えば
綿、ポリエステル、ポリオレフィン、ポリアミド、ポリ
プロピレン等の織布又は不織布が挙げられる。織布又は
不織布の厚さは、３０〜９８０μm、特に５０〜７５０
μmが好ましい。また、織布又は不織布の空隙率は５０
〜９９％、特に６０〜９９％であるのが、投錨性、塗膏
時の均一性、及び粘着性の点から好ましい。The woven fabric or nonwoven fabric is not particularly limited as long as it is generally used for a poultice. Examples thereof include woven fabrics and nonwoven fabrics of cotton, polyester, polyolefin, polyamide, polypropylene and the like. The thickness of the woven or nonwoven fabric is 30 to 980 μm, especially 50 to 750
μm is preferred. The porosity of the woven or nonwoven fabric is 50
It is preferably from 99 to 99%, particularly preferably from 60 to 99%, from the viewpoints of anchoring properties, uniformity during application and adhesion.
【００１２】ここで、空隙率は、試料における空間の占
める割合を示し、試料全体の体積を１としたときに、織
布又は不織布の原料繊維等が占める容積を除いた部分の
割合をいう。具体的には、以下の方法により求められ
る。容積が６０cm3（縦５cm×横６cm×高さ２cm）のア
クリル製容器に、５cm×６cmの大きさに裁断した織布又
は不織布（織布等という）を、圧をかけないようにいっ
ぱいに詰め、そのときの重量：MB（ブランク重量）を測
定する。そのアクリル製容器を、織布等を詰めたままデ
シケーターに入れた水中に浸け、その後減圧（４０〜５
０mmHg、３０分）にし、織布等の空隙に水を隙間なく充
填させ、そのときの重量：MSを測定する。以下の式よ
り、織布等の空隙率を求める。Here, the porosity indicates the ratio of the space occupied by the sample, and refers to the ratio of the portion excluding the volume occupied by the raw fibers of the woven or nonwoven fabric when the volume of the entire sample is 1. Specifically, it is determined by the following method. In a 60cm 3 (5cm × 6cm × 2cm height) acrylic container with a volume of 60cm 3 , fill the woven or non-woven cloth (called woven cloth etc.) cut into a size of 5cm × 6cm without applying pressure. stuffed, the weight of that time: measuring the M B (blank weight). The acrylic container is immersed in water placed in a desiccator with woven cloth or the like packed therein, and then decompressed (40 to 5).
0 mmHg, and 30 minutes), the water in the voids of the woven fabric or the like is filled without gaps, the weight of that time: measuring the M S. The porosity of a woven fabric or the like is obtained from the following equation.
【００１３】[0013]
【数１】 (Equation 1)
【００１４】このような高分子フィルムと織布又は不織
布とを積層するには、例えば接着剤を用いて貼りあわせ
たり、ヒートシールを施せば良い。ここで、接着剤とし
ては、例えばウレタン系樹脂、ポリエステル系樹脂、ア
クリル系樹脂等を使用できる。In order to laminate such a polymer film and a woven or non-woven fabric, the polymer film and the woven or non-woven fabric may be laminated, for example, using an adhesive or heat-sealed. Here, as the adhesive, for example, a urethane resin, a polyester resin, an acrylic resin, or the like can be used.
【００１５】このようにして得られる支持体は、厚さが
１mm未満、特に０．７mm以下であるのが、皮膚から剥が
れ難いので好ましい。また、支持体は、透湿度が５００
ｇ／m2／２４ｈ以下、特に２００ｇ／m2／２４ｈ以下で
あるのが、パップ剤の高分子フィルム面から膏体成分、
例えば臭い成分、水分、薬効成分等の放出が抑えられ、
無臭で、しかも薬効が持続するパップ剤が得られるので
好ましい。透湿度は、高分子フィルムの種類、厚さや、
織布又は不織布の種類、厚さ、空隙率等を選択すること
により、調整することができる。なお、透湿度は、ＪＩ
Ｓ Ｚ ０２０８「防湿包装材料の透湿度試験方法」によ
り、測定される。The support thus obtained preferably has a thickness of less than 1 mm, especially 0.7 mm or less, since it is difficult to peel off from the skin. The support has a moisture permeability of 500.
g / m 2 / 24h or less, and particularly equal to or less than 200g / m 2 / 24h, plaster component from the polymer film surface of the poultice,
For example, the release of odor components, moisture, medicinal components, etc. is suppressed,
A cataplasm that is odorless and maintains its medicinal effect is preferable. The moisture permeability depends on the type and thickness of the polymer film,
It can be adjusted by selecting the type, thickness, porosity, etc. of the woven or nonwoven fabric. The water vapor transmission rate is determined by JI
It is measured by SZ0208 “Method for testing moisture permeability of moisture-proof packaging material”.
【００１６】一方、本発明で用いる親水性基剤（膏体）
は、通常のパップ剤に用いられる成分、例えば薬効成
分、水溶性高分子、水、その他成分等を用い、通常の方
法により製造される。On the other hand, the hydrophilic base (plaster) used in the present invention
Is manufactured by a usual method using components used in a usual poultice, such as a medicinal component, a water-soluble polymer, water, and other components.
【００１７】薬効成分としては特に制限されず、例えば
消炎鎮痛剤（サリチル酸メチルやサリチル酸グリコール
等のサリチル酸エステル類、インドメタシン、ケトプロ
フェン、フェルビナク、フルルビプロフェン、イブプロ
フェン、ザルトプロフェン、ジクロフェナク又はそのナ
トリウム塩、アズレン、アズレンスルホン酸ナトリウ
ム、グリチルレチン酸、グリチルレチン酸ジカリウム、
メフェナム酸又はその誘導体、ブフェキサマック、アル
クロフェナック、プレドニゾロン又はそのエステル類、
ヒドロコルチゾン又はそのエステル類、デキサメタゾン
又はそのエステル類、ベタメタゾン又はそのエステル
類、ジフルコルトロン又はそのエステル類、ジフロラゾ
ン又はそのエステル類、フルメタゾン又はそのエステル
類、モメタゾン又はそのエステル類、アクロメタゾン又
はそのエステル類、クロベタゾール又はそのエステル
類、デプロドン又はそのエステル類、ジフルプレドナー
ト、トリアムシノロン、トリアムシノロンアセトニド、
ブデソニド、ハルシノニド、フルオシノニド、ベクロメ
タゾン、フルオシノロン、フルオシノロンアセトニド、
フルドロキシコルチド、クロベタゾン、塩酸ジフェンヒ
ドラミン、マレイン酸クロルフェニラミン、ナプロキセ
ン、ピロキシカムなど）、清涼剤（ｄｌ−カンフル、ｄ
ｌ−又はｌ−メントール等）、血行促進剤（ビタミンＥ
又はその誘導体、ノニル酸ワニリルアミド、カプサイシ
ン等）、局所麻酔剤（リドカイン、ブピバカイン、メピ
バカイン、プロカイン、テトラカイン等）、循環器用薬
（亜硝酸アミル、イノシトールヘキサニコチネート、塩
酸イソクスプリン、塩酸エタフェノン、塩酸カルボクロ
ノン、塩酸ジラゼプ、塩酸ジルチアゼム、塩酸トリメタ
ジジン、塩酸ニカルジピン、塩酸ベラパミル、ジピリダ
モール、硝酸イソソルビド、トラピジル、ニコランジ
ル、ニソルジピン、ニトレンジピン、ニトログリセリ
ン、ニフェジピン、ニルバジピン、ヘプロニカート、マ
レイン酸エナラプリル、アルトロン、エラスターゼ、ク
リノフィブラート、クロフィブラート、コレスチラミ
ン、シンフィブラート、ニコモール、ニセリトロール、
プラバスタチンナトリウム、プロブコール、ベザフィブ
ラート、メリナミド、アルガトロバン、イブジラスト、
塩酸エチレフリン、塩酸ニカルジピン、塩酸メクロフェ
ノキサート、オザグレルナトリウム、γ−アミノ酪酸、
酒石酸イフェンプロジル、ニセルゴリン、ピリジノール
カルバメート、ビンポセチン、フマル酸ニゾフェノン、
ベノプラント、マレイン酸シネパジド等）、皮膚軟化剤
（イオウ、尿素、サリチル酸等）、ホルモン剤（エスト
ラジオール等）、気管支拡張剤（ツロブテロール等）生
薬成分又はその抽出物（トウガラシエキス等の生薬軟エ
キス、センブリ流エキス等の生薬流エキス、オオバク乾
燥エキス等の生薬乾燥エキス、オオバク末等の生薬末、
アルニカチンキ等の生薬チンキ、ユーカリ油及びハッカ
油等の精油など）、角化改善剤及び／又はしわ改善剤
（レチノール、レチノイン酸、ヒアルロン酸、ヒドロキ
シ酸等）などが挙げられる。これらの薬効成分は、１種
又は２種以上を組合わせて用いることができ、配合量は
通常、親水性基剤組成物全体の０．０１〜３０重量％、
特に０．０５〜２５重量％が好ましい。The medicinal component is not particularly restricted but includes, for example, anti-inflammatory analgesics (salicylates such as methyl salicylate and glycol salicylate, indomethacin, ketoprofen, felbinac, flurbiprofen, ibuprofen, zaltoprofen, diclofenac or its sodium salt, azulene) , Sodium azulene sulfonate, glycyrrhetinic acid, dipotassium glycyrrhetinate,
Mefenamic acid or a derivative thereof, bufexamac, alclofenac, prednisolone or an ester thereof,
Hydrocortisone or its esters, dexamethasone or its esters, betamethasone or its esters, diflucortron or its esters, diflorazone or its esters, flumethasone or its esters, mometasone or its esters, acromethasone or its esters, Clobetasol or its esters, deprodone or its esters, difluprednate, triamcinolone, triamcinolone acetonide,
Budesonide, halcinonide, fluocinonide, beclomethasone, fluocinolone, fluocinolone acetonide,
Fludroxycortide, clobetasone, diphenhydramine hydrochloride, chlorpheniramine maleate, naproxen, piroxicam, etc., cooling agents (dl-camphor, d
l- or l-menthol, etc.), blood circulation enhancers (vitamin E
Or a derivative thereof, vanillyl amide nonylate, capsaicin, etc.), a local anesthetic (lidocaine, bupivacaine, mepivacaine, procaine, tetracaine, etc.), a cardiovascular drug (amyl nitrite, inositol hexanicotinate, isoxsuprine hydrochloride, etaphenone hydrochloride, carbohydrate hydrochloride) Clonone, dilazep hydrochloride, diltiazem hydrochloride, trimetazidine hydrochloride, nicardipine hydrochloride, verapamil hydrochloride, dipyridamole, isosorbide dinitrate, trapidil, nicorandil, nisoldipine, nitrendipine, nitroglycerin, nifedipine, nilvadipine, hepronicart, enalapril maleate, altron, elastase, elastase Clofibrate, cholestyramine, simfibrate, nicomol, niceritrol,
Pravastatin sodium, probucol, bezafibrate, melinamide, argatroban, ibudilast,
Ethylephrine hydrochloride, nicardipine hydrochloride, meclofenoxate hydrochloride, ozagrel sodium, γ-aminobutyric acid,
Ifenprodil tartrate, nicergoline, pyridinol carbamate, vinpocetine, nizophenone fumarate,
Benobranto, maleic acid cinepazide, etc.), emollients (sulfur, urea, salicylic acid, etc.), hormonal agents (estradiol, etc.), bronchodilators (tulobuterol, etc.), crude drug components or extracts thereof (soft extract, such as pepper extract, assembly) Herbal medicine extract such as flu extract, herbal dry extract such as psyllium dry extract, herbal powder such as psyllium powder,
Herbal tinctures such as arnica tincture, essential oils such as eucalyptus oil and peppermint oil), keratinizing agents and / or wrinkle improving agents (retinol, retinoic acid, hyaluronic acid, hydroxy acid, etc.). These medicinal components can be used alone or in combination of two or more, and the compounding amount is usually 0.01 to 30% by weight of the whole hydrophilic base composition,
Particularly, 0.05 to 25% by weight is preferable.
【００１８】これらの薬効成分の吸収促進又は持続性を
高めるために、溶解剤又は吸収促進剤を配合することも
できる。溶解剤としては、例えばオレイン酸、炭酸プロ
ピレン、ポリエチレングリコール、ミリスチン酸エステ
ル類（ミリスチン酸イソプロピル、ミリスチン酸ブチル
等）、パルミチン酸エステル類（パルミチン酸イソプロ
ピル、パルミチン酸セチル等）、ステアリン酸エステル
類（ステアリン酸ブチル、ステアリン酸イソセチル
等）、セバシン酸エステル類（セバシン酸ジエチル、セ
バシン酸ジイソプロピル等）、リノール酸エステル類
（リノール酸エチル、リノール酸イソプロピル等）、プ
ロピレングリコール、クロタミトン、オレイルアルコー
ル、ジメチルスルホキシド、ハッカ油、ユーカリ油、ヒ
マシ油、ｌ−リモネン、ｄ−リモネン、ｄｌ−リモネン
又はその他の精油類等が挙げられる。吸収促進剤として
は、例えばジイソプロピルアジペート、レシチン、スク
ワラン、スクワレン、エイゾン、ｌ−メントール、ポリ
エチレングリコール、ミリスチン酸イソプロピル、クロ
タミトン、ジメチルスルホキシド、ハッカ油、ユーカリ
油、ｄ−リモネン、ｄｌ−リモネン又はその他の精油類
などが挙げられる。これらの溶解剤又は吸収促進剤は、
１種又は２種以上を組合わせて用いることができ、配合
量は特に制限されないが、通常、親水性基剤組成物全体
の０．５〜３０重量％であるのが好ましい。A dissolving agent or an absorption enhancer may be blended in order to enhance the absorption or sustainability of these active ingredients. Examples of the solubilizer include oleic acid, propylene carbonate, polyethylene glycol, myristic esters (isopropyl myristate, butyl myristate, etc.), palmitic esters (isopropyl palmitate, cetyl palmitate, etc.), stearic esters ( Butyl stearate, isocetyl stearate, etc.), sebacic esters (diethyl sebacate, diisopropyl sebacate, etc.), linoleic esters (ethyl linoleate, isopropyl linoleate, etc.), propylene glycol, crotamiton, oleyl alcohol, dimethyl sulfoxide Mint oil, eucalyptus oil, castor oil, l-limonene, d-limonene, dl-limonene and other essential oils. Absorption enhancers include, for example, diisopropyl adipate, lecithin, squalane, squalene, azone, l-menthol, polyethylene glycol, isopropyl myristate, crotamiton, dimethyl sulfoxide, peppermint oil, eucalyptus oil, d-limonene, dl-limonene or other Essential oils and the like. These solubilizers or absorption enhancers
One type or two or more types can be used in combination, and the blending amount is not particularly limited, but is usually preferably 0.5 to 30% by weight of the whole hydrophilic base composition.
【００１９】また、薬効成分を膏体基剤中へ均一に分散
させるために、界面活性剤（レシチン誘導体、プロピレ
ングリコール脂肪酸エステル、グリセリン脂肪酸エステ
ル、ポリオキシエチレングリセリン脂肪酸エステル、ポ
リグリセリン脂肪酸エステル、ソルビタン脂肪酸エステ
ル、ポリオキシエチレンソルビタン脂肪酸エステル、ポ
リオキシエチレンソルビット脂肪酸エステル、ポリオキ
シエチレンアルキルフェニルホルムアルデヒド縮合体、
ポリオキシエチレンヒマシ油、ポリオキシエチレン硬化
ヒマシ油、ポリオキシエチレンステロール、ポリオキシ
エチレン水素添加ステロール、ポリエチレングリコール
脂肪酸エステル、ポリオキシエチレンアルキルエーテ
ル、ポリオキシエチレンポリオキシプロピレンアルキル
エーテル、ポリオキシエチレンアルキルフェニルエーテ
ル等）の１種又は２種以上を配合することもできる。配
合量は特に制限されないが、通常、親水性基剤組成物全
体の０．１〜２０重量％であるのが好ましい。In order to uniformly disperse the medicinal component in the base, a surfactant (lecithin derivative, propylene glycol fatty acid ester, glycerin fatty acid ester, polyoxyethylene glycerin fatty acid ester, polyglycerin fatty acid ester, sorbitan) is used. Fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene sorbite fatty acid ester, polyoxyethylene alkylphenyl formaldehyde condensate,
Polyoxyethylene castor oil, polyoxyethylene hardened castor oil, polyoxyethylene sterol, polyoxyethylene hydrogenated sterol, polyethylene glycol fatty acid ester, polyoxyethylene alkyl ether, polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene alkylphenyl Ether or the like can be blended. The amount is not particularly limited, but is usually preferably 0.1 to 20% by weight of the whole hydrophilic base composition.
【００２０】水溶性高分子としては、例えばゼラチン、
デンプン、寒天、マンナン、アルギン酸、アルギン酸
塩、ポリアクリル酸、ポリアクリル酸塩、デキストリ
ン、メチルセルロース、メチルセルロースナトリウム、
カルボキシメチルセルロース、カルボキシメチルセルロ
ースナトリウム、ポリビニルアルコール、ポリビニルピ
ロリドン、メチルビニルエーテル−無水マレイン酸共重
合体、カルボキシビニルポリマー、アラビアガム、トラ
ガントガム、カラヤガム、ローカストビーンガム等が挙
げられ、１種又は２種以上を組合わせて用いることがで
きる。これらの水溶性高分子は、通常、親水性基剤組成
物全体の０．５〜５０重量％、特に１〜２０重量％配合
するのが好ましい。この割合が少なすぎるとゲル形成が
困難であり、逆に多すぎると水溶性高分子が均一に溶解
し難くなる。また、水は通常、親水性基剤組成物全体の
２０〜８０重量％、特に２５〜７０重量％配合するのが
好ましい。Examples of the water-soluble polymer include gelatin,
Starch, agar, mannan, alginic acid, alginate, polyacrylic acid, polyacrylate, dextrin, methylcellulose, methylcellulose sodium,
Carboxymethylcellulose, sodium carboxymethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, methyl vinyl ether-maleic anhydride copolymer, carboxyvinyl polymer, gum arabic, tragacanth gum, karaya gum, locust bean gum, and the like. They can be used together. These water-soluble polymers are generally preferably incorporated in an amount of 0.5 to 50% by weight, particularly 1 to 20% by weight, based on the entire hydrophilic base composition. If this ratio is too small, gel formation is difficult, and if it is too large, the water-soluble polymer is difficult to dissolve uniformly. In addition, it is usually preferable that water is blended in an amount of 20 to 80% by weight, particularly 25 to 70% by weight of the entire hydrophilic base composition.
【００２１】それ以外の成分としては、通常膏体成分と
して用いられるものであれば特に限定されず、例えば保
湿剤（濃グリセリン、グリセリン、ソルビトール、乳
酸、尿素、プロピレングリコール、エチレングリコー
ル、ジエチレングリコール、トリエチレングリコール、
ポリエチレングリコール、１，３−ブチレングリコール
等）、無機粉体（カオリン、酸化チタン、タルク、ベン
トナイト、酸化亜鉛、モンモリロナイト、無水ケイ酸
等）、架橋剤（アルミニウム化合物、マグネシウム化合
物、カルシウム化合物等）、防腐剤（チモール、塩化ベ
ンザルコニウム、パラベン類等）、抗酸化剤（アスコル
ビン酸、ステアリン酸エステル、没食子酸エステル、エ
デト酸二ナトリウム、ジブチルヒドロキシトルエン、ブ
チルヒドロキシアニソール等）、ｐＨ調整剤（リン酸、
ホウ酸、クエン酸、酢酸、リンゴ酸、酒石酸、乳酸及び
それらの塩、水酸化ナトリウム、ジエタノールアミン、
トリエタノールアミン、ジイソプロパノールアミン
等）、香料、色素などを、本発明の効果を損なわない範
囲で適宜配合することができる。The other components are not particularly limited as long as they are usually used as a plaster component. For example, humectants (concentrated glycerin, glycerin, sorbitol, lactic acid, urea, propylene glycol, ethylene glycol, diethylene glycol, triethylene glycol) ethylene glycol,
Polyethylene glycol, 1,3-butylene glycol, etc.), inorganic powders (kaolin, titanium oxide, talc, bentonite, zinc oxide, montmorillonite, silicic anhydride, etc.), crosslinking agents (aluminum compounds, magnesium compounds, calcium compounds, etc.), Preservatives (thymol, benzalkonium chloride, parabens, etc.), antioxidants (ascorbic acid, stearic acid ester, gallic acid ester, disodium edetate, dibutylhydroxytoluene, butylhydroxyanisole, etc.), pH adjusters (phosphorous acid,
Boric acid, citric acid, acetic acid, malic acid, tartaric acid, lactic acid and their salts, sodium hydroxide, diethanolamine,
Triethanolamine, diisopropanolamine, etc.), fragrances, dyes, and the like can be appropriately compounded as long as the effects of the present invention are not impaired.
【００２２】これらの成分を用いて得られる親水性基剤
は、粘度が６０万〜１２００万mPa・s、特に７０万〜１
０００万mPa・sであるのが好ましい。６０万mPa・s未満
の低粘度の膏体では、製造時にはみ出しが生じたり、ま
た、柔らかすぎることで残膏がみられ、使用感において
十分でなく、１２００万mPa・sを超える粘度では織布又
は不織布に膏体を十分かつ均一に含浸させるのが難し
く、製造時における塗膏量の精度が得られない場合があ
り、また十分な粘着力も得られない。ここで、粘度は、
第１３改正日本薬局方第一部、一般試験法「36. 粘度測
定法第２法 回転粘度計法」に準じ、装置として (2)単
一円筒形回転粘度計を用い、２０℃において測定するも
のである。The hydrophilic base obtained by using these components has a viscosity of 600,000 to 12,000,000 mPa · s, especially 700,000 to 1
Preferably, it is 10 million mPa · s. In the case of a low-viscosity plaster of less than 600,000 mPa · s, bleeding may occur at the time of manufacture, and a residual plaster may be seen due to being too soft, and the feeling of use may not be sufficient. It is difficult to impregnate the cloth or nonwoven fabric with the plaster sufficiently and uniformly, so that the accuracy of the plaster amount at the time of production may not be obtained, and sufficient adhesive strength may not be obtained. Here, the viscosity is
According to the 13th Revised Japanese Pharmacopoeia First Part, General Test Method "36. Viscosity Measurement Method 2, Rotary Viscometer Method" (2) Measure at 20 ° C using a single cylindrical rotary viscometer. Things.
【００２３】本発明のパップ剤は、例えば支持体の織布
又は不織布層側に親水性基剤を塗布・含浸させ、更にポ
リプロピレンフィルム等のライナーを添着した後、裁断
することにより製造される。また、ライナー上に親水性
基剤を塗布し、これに支持体の織布又は不織布面を被せ
て含浸させた後、裁断することによっても製造できる。
更に、親水性基剤を支持体の織布又は不織布層側とライ
ナーに挟みながら織布又は不織布層に含浸させた後、裁
断することにより、製造することもできる。The poultice of the present invention is produced, for example, by applying and impregnating a hydrophilic base on the side of the woven or non-woven fabric layer of the support, further attaching a liner such as a polypropylene film, and then cutting. Alternatively, it can be produced by applying a hydrophilic base material on a liner, covering the surface with a woven or non-woven fabric surface of a support, impregnating the support, and then cutting.
Furthermore, it can also be produced by impregnating a woven fabric or nonwoven fabric layer with a hydrophilic base material sandwiched between a woven fabric or nonwoven fabric layer side of a support and a liner, followed by cutting.
【００２４】これらの場合、支持体に対する親水性基剤
の塗膏量は、求めるパップ剤の厚さに応じて適宜設定す
れば良い。本発明においては、支持体の高分子フィルム
と織布又は不織布の接着面まで（高分子フィルムと織布
又は不織布を接着剤で貼りあわせた場合には接着剤層面
まで）、すなわち織布又は不織布の厚さ全体に、親水性
基剤が含浸されているのが好ましい（図１（２）参
照）。In these cases, the amount of the hydrophilic base applied to the support may be appropriately set according to the required thickness of the cataplasm. In the present invention, up to the adhesive surface between the polymer film of the support and the woven or non-woven fabric (up to the adhesive layer surface when the polymer film and the woven or non-woven fabric are bonded with an adhesive), that is, the woven or non-woven fabric Is preferably impregnated with a hydrophilic base material over the entire thickness (see FIG. 1 (2)).
【００２５】親水性基剤層の厚さは、織布又は不織布に
含浸される分も含めて、５０〜９００μm、特に１００
〜７００μmであるのが好ましい。また、この厚さは、
織布又は不織布表面に親水性基剤面が形成されるのに十
分な厚さであることが必要であり、織布又は不織布に含
浸されていない部分の層の厚さが２０μm以上、特に５
０μm以上であるのが、皮膚への粘着性の点で好まし
い。The thickness of the hydrophilic base layer is 50 to 900 μm, especially 100 to 100 μm, including that which is impregnated in a woven or nonwoven fabric.
Preferably it is ~ 700 µm. Also, this thickness is
It is necessary that the thickness is sufficient to form a hydrophilic base surface on the surface of the woven or nonwoven fabric, and the thickness of the layer not impregnated in the woven or nonwoven fabric is 20 μm or more, especially 5 μm.
It is preferably at least 0 μm from the viewpoint of adhesiveness to the skin.
【００２６】このようにして得られる本発明のパップ剤
は、厚さ１００〜１０００μm、好ましくは２００〜９
００μm、特に好ましくは３００〜７００μmである。１
０００μmを超えるものは、皮膚から剥がれやすい。The cataplasm of the present invention thus obtained has a thickness of 100 to 1000 μm, preferably 200 to 9 μm.
00 μm, particularly preferably 300 to 700 μm. 1
Those having a size exceeding 000 μm are easily peeled from the skin.
【００２７】[0027]
【発明の効果】本発明のパップ剤は、薄くて剥がれ難
く、皮膚への粘着性が改善され、使用感に優れたもので
ある。また、塗膏する膏体量が最小限に抑えられること
より製造コストが低減でき、また、治療に必要な薬物量
が抑えられ、薬物利用率を改善することが可能となる。
さらに、支持体の透湿度をコントロールすることによ
り、膏体成分、特に臭い成分の放出が抑えられ、無臭で
かつ薄型のパップ剤が得られる。また、パップ剤からの
水分や薬効成分の揮散も抑えられ、使用後にパップ剤を
剥離するときの刺激が低減され、薬効も持続する。The poultice of the present invention is thin and hard to peel off, has improved adhesiveness to the skin, and is excellent in usability. Further, the production cost can be reduced by minimizing the amount of plaster to be applied, and the amount of drug required for treatment can be suppressed, and the drug utilization can be improved.
Further, by controlling the moisture permeability of the support, the release of the plaster component, particularly the odor component, is suppressed, and an odorless and thin cataplasm is obtained. In addition, volatilization of water and medicinal components from the poultice is suppressed, and irritation when peeling the poultice after use is reduced, and the medicinal effect is maintained.
【００２８】[0028]
【実施例】次に、実施例を挙げて、本発明をさらに具体
的に説明するが、本発明はこれら実施例等になんら制約
されるものではない。なお、実施例において用いた親水
性基剤の処方No.1〜4は、以下のとおりである。EXAMPLES Next, the present invention will be described more specifically with reference to examples, but the present invention is not limited to these examples. In addition, the prescription No. 1-4 of the hydrophilic base used in the Example is as follows.
【００２９】[0029]
【表１】 [Table 1]
【００３０】(処方No.1及びNo.3の製造) (i)成分(1)〜(3)を混合し、次いで成分(10)を加えてよ
く混ぜる。 (ii)これに、成分(6)〜(8)及び(12)を加えて混合し、更
に成分(11)を加えてよく混ぜる。 (iii)別に、成分(9)を少量の成分(13)に溶かし、これを
(ii)に加えてよく混ぜる。 (iv)更に、残りの成分(13)を徐々に加えながらよく混
ぜ、親水性基剤を得た。(Production of Formulation Nos. 1 and 3) (i) Components (1) to (3) are mixed, and then component (10) is added and mixed well. (ii) Components (6) to (8) and (12) are added to and mixed with this, and component (11) is further added and mixed well. (iii) Separately, dissolve component (9) in a small amount of component (13),
Mix well with (ii). (iv) Further, the remaining component (13) was gradually added and mixed well to obtain a hydrophilic base.
【００３１】(処方No.2の製造) (i)成分(4)を成分(5)に溶解し、これに成分(10)を加え
てよく混ぜる。 (ii)これに、成分(6)〜(8)及び(12)を加えて混合し、更
に成分(11)を加えてよく混ぜる。 (iii)別に、成分(9)を少量の成分(13)に溶かし、これを
(ii)に加えてよく混ぜる。 (iv)更に、残りの成分(13)を徐々に加えながらよく混
ぜ、親水性基剤を得た。(Production of Formulation No. 2) (i) The component (4) is dissolved in the component (5), and the component (10) is added thereto and mixed well. (ii) Components (6) to (8) and (12) are added to and mixed with this, and component (11) is further added and mixed well. (iii) Separately, dissolve component (9) in a small amount of component (13),
Mix well with (ii). (iv) Further, the remaining component (13) was gradually added and mixed well to obtain a hydrophilic base.
【００３２】(処方No.4の製造) (i)成分(1)〜(3)を混合し、次いで成分(10)を加えてよ
く混ぜる。 (ii)これに、成分(6)〜(8)及び(12)を加えて混合し、更
に成分(11)を加えてよく混ぜる。 (iii)更に、成分(13)を徐々に加えながらよく混ぜ、親
水性基剤を得た。(Production of Formulation No. 4) (i) Components (1) to (3) are mixed, and then component (10) is added and mixed well. (ii) Components (6) to (8) and (12) are added to and mixed with this, and component (11) is further added and mixed well. (iii) Further, the component (13) was gradually added and mixed well to obtain a hydrophilic base.
【００３３】実施例１ ポリエステルフィルム（厚さ４μm）とポリエステル不
織布（厚さ０．４mm、空隙率７９％）とを、接着剤を用
いて接着して得られた支持体（厚さ０．４mm、透湿度１
２６ｇ／m2／２４ｈ）の不織布側に、処方No.1の膏体を
展延し、ポリプロピレン製のライナーを添着した後、所
定の大きさに裁断して、パップ剤を得た（厚さ０．５m
m）。Example 1 A support (0.4 mm thick) obtained by bonding a polyester film (4 μm thick) and a polyester nonwoven fabric (0.4 mm thick, porosity 79%) using an adhesive. , Moisture permeability 1
The nonwoven side of 26g / m 2 / 24h), to spread the plaster formulation No.1, after impregnated with polypropylene liner, and cut into a predetermined size to obtain a poultice (thickness 0.5m
m).
【００３４】実施例２ 処方No.2の膏体を用いる以外は実施例１と同様にして、
パップ剤を製造した（厚さ０．５mm）。Example 2 The procedure of Example 1 was repeated, except that the paste of Formulation No. 2 was used.
A poultice was produced (thickness 0.5 mm).
【００３５】実施例３ ポリウレタンフィルム（厚さ２０μm）とポリエステル
不織布（厚さ０．４mm、空隙率５８％）とを、接着剤を
用いて接着して得られた支持体（厚さ０．４２mm、透湿
度２８００ｇ／m2／２４ｈ）を用いる以外は実施例１と
同様にして、パップ剤を製造した（厚さ０．８mm）。Example 3 A support (0.42 mm thick) obtained by bonding a polyurethane film (20 μm thick) and a polyester nonwoven fabric (0.4 mm thick, porosity 58%) using an adhesive. but using moisture permeability 2800g / m 2 / 24h) in the same manner as in example 1 to produce a poultice (thickness 0.8 mm).
【００３６】実施例４ 処方No.3の膏体を用いる以外は実施例１と同様にして、
パップ剤を製造した（厚さ０．５mm）。Example 4 The procedure of Example 1 was repeated except that the paste of Formulation No. 3 was used.
A poultice was produced (thickness 0.5 mm).
【００３７】実施例５ 処方No.4の膏体を用いる以外は実施例１と同様にして、
パップ剤を製造した（厚さ０．５mm）。Example 5 The procedure of Example 1 was repeated, except that the paste of Formulation No. 4 was used.
A poultice was produced (thickness 0.5 mm).
【００３８】実施例６ ポリウレタンフィルム（厚さ２０μm）とポリエステル
不織布（厚さ０．４mm、空隙率５８％）とを、接着剤を
用いて接着して得られた支持体（厚さ０．４２mm、透湿
度２８００ｇ／m2／２４ｈ）を用いる以外は実施例１と
同様にして、パップ剤を製造した（厚さ０．５mm）。Example 6 A support (0.42 mm thick) obtained by bonding a polyurethane film (20 μm thick) and a polyester nonwoven fabric (0.4 mm thick, porosity 58%) using an adhesive. but using moisture permeability 2800g / m 2 / 24h) in the same manner as in example 1 to produce a poultice (thickness 0.5 mm).
【００３９】比較例１ ポリエステルフィルム（厚さ４μm）とポリエステル不
織布（厚さ１．２mm、空隙率９３％）とを、接着剤を用
いて接着して得られた支持体（厚さ１．２mm、透湿度１
０８ｇ／m2／２４ｈ）を用いる以外は実施例１と同様に
して、パップ剤を製造した（厚さ１．４mm）。Comparative Example 1 A support (1.2 mm thick) obtained by bonding a polyester film (4 μm thick) and a polyester nonwoven fabric (1.2 mm thick, porosity 93%) using an adhesive. , Moisture permeability 1
08g / m 2 / 24h) except for using in the same manner as in Example 1 to produce a poultice (thickness 1.4 mm).
【００４０】比較例２ ポリエステル不織布（厚さ１．２ｍｍ、空隙率９３％）
からなる支持体を用いる以外は実施例１と同様にして、
パップ剤を製造した（厚さ１．４mm）。Comparative Example 2 Polyester nonwoven fabric (thickness: 1.2 mm, porosity: 93%)
In the same manner as in Example 1 except that a support consisting of
A poultice was produced (1.4 mm thick).
【００４１】比較例３ 処方No.2の膏体を用いる以外は比較例２と同様にして、
パップ剤を製造した（厚さ１．４mm）。Comparative Example 3 The procedure of Comparative Example 2 was repeated except that the paste of Formulation No. 2 was used.
A poultice was produced (1.4 mm thick).
【００４２】[0042]
【表２】 [Table 2]
【００４３】実施例１〜６で得られた本発明のパップ剤
はいずれも、高分子フィルムと不織布の接着面まで親水
性基剤が含浸され、かつ不織布表面に親水性基剤面が形
成されており、薄くて剥がれ難く、使用感に優れてい
た。また、支持体の透湿度が５００ｇ／m2／２４ｈ以下
である実施例１、２、４及び５では、膏体成分の臭いが
より抑えられていた。さらに、親水性基剤の粘度が６０
万〜１２００万mPa・sである処方No.1又はNo.2を用いた
実施例１〜３及び６では、使用感及び粘着力により優れ
ていた。これに対し、比較例１〜３のパップ剤は、厚さ
が厚く、剥がれやすいものであった。Each of the poultices of the present invention obtained in Examples 1 to 6 was impregnated with the hydrophilic base up to the bonding surface between the polymer film and the nonwoven fabric, and formed with the hydrophilic base surface on the nonwoven fabric surface. It was thin and hard to peel off, and was excellent in usability. Further, the moisture permeability of the support in Examples 1, 2, 4 and 5 or less 500g / m 2 / 24h, odor plaster component has been further suppressed. Further, the viscosity of the hydrophilic base is 60
In Examples 1 to 3 and 6 using Formulation No. 1 or No. 2 of 10,000 to 12,000,000 mPa · s, the feeling in use and the adhesive strength were excellent. On the other hand, the poultices of Comparative Examples 1 to 3 were thick and easily peeled off.
【００４４】実施例７ （１）膏体の調製；表３に示す組成の膏体を調製した。
すなわち、まず、成分(1)〜(3)、(6)、(11)、(19)及び
(20)を混ぜ合わせ、これに成分(10)を加えてよく混ぜ
る。次に、成分(7)及び(13)〜(17)を加えてよく混ぜ、
更に成分(9)を加えてよく混ぜる。別に、成分(8)を少量
の成分(21)に溶かし、これを先の混合物に加えてよく混
ぜる。また別に、成分(18)を少量の成分(21)に溶かし、
これを先の混合物に加えてよく混ぜる。次いで、残りの
成分(21)を徐々に加えながらよく混ぜ、膏体を得る。膏
体の粘度は、１２０万mPa・sであった。Example 7 (1) Preparation of plaster: A plaster having the composition shown in Table 3 was prepared.
That is, first, components (1) to (3), (6), (11), (19) and
Combine (20), add component (10) and mix well. Next, add the components (7) and (13) to (17) and mix well,
Add component (9) and mix well. Separately, dissolve component (8) in a small amount of component (21), add this to the above mixture and mix well. Separately, dissolve component (18) in a small amount of component (21),
Add this to the previous mixture and mix well. Next, the remaining component (21) is gradually added and mixed well to obtain a paste. The viscosity of the plaster was 1.2 million mPa · s.
【００４５】（２）パップ剤の製造；（１）で得た膏体
を、支持体とライナーに挟みながら一定の圧を加えて塗
膏し、適当な大きさに裁断してパップ剤を得た。支持体
としては、ポリエステルフィルム（厚さ４μｍ）とポリ
エステル不織布（厚さ０．４mm、空隙率７９％）とを、
接着剤を用いて接着したもの（厚さ０．４mm、透湿度１
２６ｇ／m2／２４ｈ）を用いた。得られたパップ剤の厚
さは５４０μmであった。(2) Production of a poultice: The plaster obtained in (1) is applied by applying a certain pressure while sandwiched between a support and a liner, and cut into a suitable size to obtain a poultice. Was. As a support, a polyester film (thickness 4 μm) and a polyester non-woven fabric (thickness 0.4 mm, porosity 79%) were used.
Bonded with an adhesive (thickness 0.4 mm, moisture permeability 1)
26g / m 2 / 24h) was used. The thickness of the obtained poultice was 540 μm.
【００４６】実施例８ （１）膏体の調製；表３に示す組成の膏体を製造した。
すなわち、成分(2)、(4)〜(6)、(11)、(19)及び(20)を
混ぜ合わせ、これに成分(10)を加えてよく混ぜる。次
に、成分(7)、(14)、(16)及び(17)を加えてよく混ぜ、
更に成分(9)を加えてよく混ぜる。別に、成分(12)を少
量の成分(21)に溶かし、これを先の混合物に加えてよく
混ぜる。また別に、成分(8)を少量の成分(21)に溶か
し、これを先の混合物に加えてよく混ぜる。また別に、
成分(18)を少量の成分(21)に溶かし、これを先の混合物
に加えてよく混ぜる。次いで、残りの成分(21)を徐々に
加えながらよく混ぜ、膏体を得る。膏体の粘度は、２１
０万mPa・sであった。Example 8 (1) Preparation of a plaster; A plaster having the composition shown in Table 3 was produced.
That is, the components (2), (4) to (6), (11), (19) and (20) are mixed, and the component (10) is added thereto and mixed well. Next, add the components (7), (14), (16) and (17) and mix well,
Add component (9) and mix well. Separately, dissolve component (12) in a small amount of component (21), add this to the above mixture and mix well. Separately, dissolve component (8) in a small amount of component (21), add this to the above mixture, and mix well. Separately
Dissolve component (18) in a small amount of component (21), add this to the above mixture and mix well. Next, the remaining component (21) is gradually added and mixed well to obtain a paste. The viscosity of the plaster is 21
It was 100,000 mPa · s.
【００４７】（２）パップ剤の製造；（１）で得た膏体
を、支持体とライナーに挟みながら一定の圧を加えて塗
膏し、適当な大きさに裁断してパップ剤を得た。支持体
としては、実施例７と同様のものを用いた。得られたパ
ップ剤の厚さは６１０μｍであった。(2) Production of poultice: The plaster obtained in (1) is applied by applying a certain pressure while being sandwiched between a support and a liner, and cut into an appropriate size to obtain a poultice. Was. The same support as in Example 7 was used. The thickness of the obtained poultice was 610 μm.
【００４８】[0048]
【表３】 [Table 3]
【００４９】実施例７及び８で得られたパップ剤は、高
分子フィルムと不織布の接着面まで親水性基剤が含浸さ
れ、かつ不織布表面に親水性基剤面が形成されており、
薄くて剥がれ難く、使用感に優れていた。The cataplasms obtained in Examples 7 and 8 were impregnated with the hydrophilic base up to the bonding surface between the polymer film and the nonwoven fabric, and had the hydrophilic base surface formed on the nonwoven fabric surface.
It was thin and hard to peel off, and was excellent in usability.
【００５０】比較例４ 実施例７において、支持体として、ポリエステル不織布
（厚さ０．４mm、空隙率７９％）からなる支持体を用い
る以外は実施例７と同様にして、パップ剤を製造した。
得られたパップ剤の厚さは６１０μmであった。Comparative Example 4 A cataplasm was prepared in the same manner as in Example 7, except that a support made of a polyester nonwoven fabric (thickness 0.4 mm, porosity 79%) was used as the support. .
The thickness of the obtained poultice was 610 μm.
【００５１】比較例５ 実施例７において、支持体として、ポリエステル不織布
（厚さ１．２mm、空隙率９３％）からなる支持体を用い
る以外は実施例７と同様にして、パップ剤を製造した。
得られたパップ剤の厚さは１．４mmであった。Comparative Example 5 A cataplasm was prepared in the same manner as in Example 7, except that a support made of a polyester non-woven fabric (thickness: 1.2 mm, porosity: 93%) was used. .
The thickness of the obtained poultice was 1.4 mm.
【００５２】試験例１ 実施例７、比較例４及び比較例５で得られたパップ剤に
ついて、薬効成分（サリチル酸グリコール）のヒト皮膚
吸収量を測定した。すなわち、各パップ剤を５cm×７cm
に切り取り、必要な数だけヒト皮膚（背部）に貼り付
け、経時的に剥ぎ取って試料とした。それぞれの試料中
のサリチル酸グリコール量を液体クロマトグラフ法によ
り定量し、サリチル酸グリコールのヒト皮膚吸収量を求
めた。結果を図１に示す。Test Example 1 With respect to the poultices obtained in Example 7, Comparative Examples 4 and 5, the medicinal component (glycol salicylate) absorption in human skin was measured. That is, each cataplasm is 5cm x 7cm
To the human skin (back) as necessary, and peeled off over time to obtain a sample. The amount of glycol salicylate in each sample was determined by liquid chromatography, and the amount of glycol salicylate absorbed into human skin was determined. The results are shown in FIG.
【００５３】図１の結果より、高分子フィルムと不織布
を積層した支持体を用いた本発明のパップ剤は、不織布
のみからなる支持体を用いた比較品に比べ、薬効成分の
単位吸収量が高いことが確認された。From the results shown in FIG. 1, it can be seen that the cataplasm of the present invention using a support in which a polymer film and a nonwoven fabric are laminated has a unit absorption of a medicinal component in comparison with a comparative product using a support consisting of only a nonwoven fabric. It was confirmed that it was high.
【００５４】試験例２ 実施例７及び比較例５で得られたパップ剤について、皮
膚に貼付したときの使用感を評価した。すなわち、５cm
×７cmに切り取った各パップ剤を、左右の前腕に貼り、
６時間後に剥離した。貼付中の臭い（臭いが気にならな
い）、粘着性（皮膚によくつく）及び総合評価につい
て、１０名のパネラーにより、実施例と比較例を比べ
て、どちらが優れているかを官能評価した。結果を表４
に示す。なお、結果は、優れていると評価したパネラー
の人数により示した。Test Example 2 With respect to the cataplasms obtained in Example 7 and Comparative Example 5, the feeling of use when applied to the skin was evaluated. That is, 5cm
Paste each patch cut to × 7cm on the left and right forearms,
Peeled off after 6 hours. With regard to the odor (the odor was not noticeable), the tackiness (it adheres well to the skin), and the overall evaluation during the application, ten panelists compared the examples with the comparative examples, and conducted a sensory evaluation as to which was better. Table 4 shows the results
Shown in In addition, the result was shown by the number of panelists who evaluated that it was excellent.
【００５５】[0055]
【表４】 [Table 4]
【００５６】表４の結果より、本発明のパップ剤は、従
来のパップ剤に比べ、貼付中の臭いが抑えられ、皮膚へ
のつきも良好で、使用感に優れたものであった。また、
本発明のパップ剤は、薄いにもかかわらず貼りやすく、
剥離時の刺激感もなかった。From the results shown in Table 4, the poultice of the present invention was superior in odor during application, had good adhesion to the skin, and was excellent in use feeling, as compared with the conventional poultices. Also,
The poultice of the present invention is easy to apply despite being thin,
There was no irritation at the time of peeling.
【図１】パップ剤の断面図を示す図である。FIG. 1 is a diagram showing a cross-sectional view of a poultice.
【図２】試験例１において、サリチル酸グリコールの単
位吸収量の経時変化を示す図である。FIG. 2 is a diagram showing a change over time in the unit absorption amount of glycol salicylate in Test Example 1.
───────────────────────────────────────────────────── フロントページの続き Ｆターム(参考） 4C076 AA74 AA77 BB31 CC05 DD28 DD30 DD34 DD37 DD38 DD43 EE03 EE09 EE24 EE32 EE42 FF52 FF56 ──────────────────────────────────────────────────続 き Continued on the front page F term (reference) 4C076 AA74 AA77 BB31 CC05 DD28 DD30 DD34 DD37 DD38 DD43 EE03 EE09 EE24 EE32 EE42 FF52 FF56
Claims (4)
層した支持体の、織布又は不織布層に親水性基剤が含浸
され、かつ織布又は不織布表面に親水性基剤面が形成さ
れ、厚さが１００〜１０００μmであるパップ剤。1. A support in which a polymer film and a woven or nonwoven fabric are laminated, wherein a woven or nonwoven fabric layer is impregnated with a hydrophilic base and a woven or nonwoven fabric surface is formed with a hydrophilic base surface. And a poultice having a thickness of 100 to 1000 μm.
mで、空隙率５０〜９９％である請求項１記載のパップ
剤。2. A woven or non-woven fabric having a thickness of 30 to 980 μm.
The poultice according to claim 1, wherein the porosity is 50 to 99% in m.
mPa・sである請求項１又は２記載のパップ剤。3. The viscosity of the hydrophilic base is from 600,000 to 12,000,000.
3. The poultice according to claim 1, which has a mPa · s.
以下である請求項１〜３のいずれか１項記載のパップ
剤。Moisture permeability wherein the support is 500g / m 2 / 24h
The poultice according to any one of claims 1 to 3, which is:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000023766A JP2001213768A (en) | 2000-02-01 | 2000-02-01 | Poultice |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000023766A JP2001213768A (en) | 2000-02-01 | 2000-02-01 | Poultice |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001213768A true JP2001213768A (en) | 2001-08-07 |
| JP2001213768A5 JP2001213768A5 (en) | 2007-03-15 |
Family
ID=18549878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000023766A Pending JP2001213768A (en) | 2000-02-01 | 2000-02-01 | Poultice |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001213768A (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005516991A (en) * | 2002-02-01 | 2005-06-09 | ミセル・プロダクツ・インコーポレイテッド | Β-carotene clear micellar formulation for treatment of leukoplakia |
| JP2008508954A (en) * | 2004-08-05 | 2008-03-27 | コリウム インターナショナル， インコーポレイテッド | Adhesive composition |
| JPWO2009154086A1 (en) * | 2008-06-17 | 2011-11-24 | 住友精化株式会社 | Acrylate-based water-soluble polymer and gelling base |
| JP2012102083A (en) * | 2010-10-12 | 2012-05-31 | Lion Corp | Skin disease therapeutic agent |
| US8273405B2 (en) | 2001-05-01 | 2012-09-25 | A.V. Topcheiv Institute of Petrochemical Synthesis, Russian Academy of Sciences | Water-absorbent adhesive compositions and associated methods of manufacture and use |
| US8481071B2 (en) | 2001-05-01 | 2013-07-09 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
| US8481059B2 (en) | 2001-05-01 | 2013-07-09 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Hydrogel compositions |
| US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
| JP2013231021A (en) * | 2012-05-01 | 2013-11-14 | Jem International Inc | Plaster |
| US8658201B2 (en) | 2004-01-30 | 2014-02-25 | Corium International, Inc. | Rapidly dissolving film for delivery of an active agent |
| US8784879B2 (en) | 2009-01-14 | 2014-07-22 | Corium International, Inc. | Transdermal administration of tamsulosin |
| US8821901B2 (en) | 2001-05-01 | 2014-09-02 | A.V. Topchiev Institute Of Petrochemical Synthesis Russian Academy Of Sciences | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
| US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
| USRE45666E1 (en) | 2000-07-07 | 2015-09-08 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
Citations (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62258318A (en) * | 1986-04-30 | 1987-11-10 | Yoshihiro Kato | Plaster |
| JPS63238017A (en) * | 1987-03-26 | 1988-10-04 | Teikoku Seiyaku Kk | Water-based plaster for external use containing carteolol hydrochloride |
| JPH01250252A (en) * | 1987-12-07 | 1989-10-05 | Fueritsuku Kk | Hot compress structure |
| JPH01321967A (en) * | 1988-06-22 | 1989-12-27 | Kanai Hiroyuki | Base fabric for cataplasm |
| JPH05201879A (en) * | 1990-05-30 | 1993-08-10 | Yamanouchi Pharmaceut Co Ltd | Percutaneous administration pharmaceutical |
| JPH06145047A (en) * | 1992-11-06 | 1994-05-24 | Maeda Yakuhin Kogyo Kk | Hydrous skin patch for external use having improved utility |
| JPH06145053A (en) * | 1992-11-06 | 1994-05-24 | Maeda Yakuhin Kogyo Kk | Anti-inflammatory analgesic skin patch for external use, having excellent utility |
| JPH0733647A (en) * | 1993-07-19 | 1995-02-03 | Sekisui Chem Co Ltd | Production of base for fomentation |
| JPH07316043A (en) * | 1994-05-25 | 1995-12-05 | Sekisui Chem Co Ltd | Plaster for medical purpose |
| JPH08104623A (en) * | 1994-10-05 | 1996-04-23 | Sekisui Chem Co Ltd | Application agent for medical use |
| JPH09110679A (en) * | 1995-10-13 | 1997-04-28 | Nitto Denko Corp | Cataplasm |
| JPH09118615A (en) * | 1995-08-24 | 1997-05-06 | Kao Corp | Water-soluble cataplasm composition |
| JPH09208460A (en) * | 1996-01-31 | 1997-08-12 | Lion Corp | Cataplasm |
| JPH09208469A (en) * | 1996-02-02 | 1997-08-12 | Mikasa Seiyaku Kk | Percutaneous absorption pasting agent |
| JPH09309823A (en) * | 1996-05-20 | 1997-12-02 | Sekisui Chem Co Ltd | Percutaneous patch material |
| JPH10109945A (en) * | 1996-10-04 | 1998-04-28 | Hisamitsu Pharmaceut Co Inc | Plasticizing agent and cataplasm containing the same |
| JPH10182450A (en) * | 1996-12-27 | 1998-07-07 | Ss Pharmaceut Co Ltd | External composition |
| JPH10265373A (en) * | 1997-03-26 | 1998-10-06 | Lion Corp | Tacky adhesive composition and poultice |
| JPH10298066A (en) * | 1997-04-24 | 1998-11-10 | Taisho Pharmaceut Co Ltd | Hot patch |
| JPH111428A (en) * | 1997-06-10 | 1999-01-06 | Ooshin Seiyaku Kk | Warmth-giving cataplasm sheet |
| JPH1129434A (en) * | 1997-07-09 | 1999-02-02 | Kao Corp | Sheet-like pack cosmetic |
| JPH11188054A (en) * | 1997-12-25 | 1999-07-13 | Lion Corp | Ex-dermal material |
| JP2000297033A (en) * | 1999-04-14 | 2000-10-24 | Hisamitsu Pharmaceut Co Inc | Cataplasm |
-
2000
- 2000-02-01 JP JP2000023766A patent/JP2001213768A/en active Pending
Patent Citations (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62258318A (en) * | 1986-04-30 | 1987-11-10 | Yoshihiro Kato | Plaster |
| JPS63238017A (en) * | 1987-03-26 | 1988-10-04 | Teikoku Seiyaku Kk | Water-based plaster for external use containing carteolol hydrochloride |
| JPH01250252A (en) * | 1987-12-07 | 1989-10-05 | Fueritsuku Kk | Hot compress structure |
| JPH01321967A (en) * | 1988-06-22 | 1989-12-27 | Kanai Hiroyuki | Base fabric for cataplasm |
| JPH05201879A (en) * | 1990-05-30 | 1993-08-10 | Yamanouchi Pharmaceut Co Ltd | Percutaneous administration pharmaceutical |
| JPH06145047A (en) * | 1992-11-06 | 1994-05-24 | Maeda Yakuhin Kogyo Kk | Hydrous skin patch for external use having improved utility |
| JPH06145053A (en) * | 1992-11-06 | 1994-05-24 | Maeda Yakuhin Kogyo Kk | Anti-inflammatory analgesic skin patch for external use, having excellent utility |
| JPH0733647A (en) * | 1993-07-19 | 1995-02-03 | Sekisui Chem Co Ltd | Production of base for fomentation |
| JPH07316043A (en) * | 1994-05-25 | 1995-12-05 | Sekisui Chem Co Ltd | Plaster for medical purpose |
| JPH08104623A (en) * | 1994-10-05 | 1996-04-23 | Sekisui Chem Co Ltd | Application agent for medical use |
| JPH09118615A (en) * | 1995-08-24 | 1997-05-06 | Kao Corp | Water-soluble cataplasm composition |
| JPH09110679A (en) * | 1995-10-13 | 1997-04-28 | Nitto Denko Corp | Cataplasm |
| JPH09208460A (en) * | 1996-01-31 | 1997-08-12 | Lion Corp | Cataplasm |
| JPH09208469A (en) * | 1996-02-02 | 1997-08-12 | Mikasa Seiyaku Kk | Percutaneous absorption pasting agent |
| JPH09309823A (en) * | 1996-05-20 | 1997-12-02 | Sekisui Chem Co Ltd | Percutaneous patch material |
| JPH10109945A (en) * | 1996-10-04 | 1998-04-28 | Hisamitsu Pharmaceut Co Inc | Plasticizing agent and cataplasm containing the same |
| JPH10182450A (en) * | 1996-12-27 | 1998-07-07 | Ss Pharmaceut Co Ltd | External composition |
| JPH10265373A (en) * | 1997-03-26 | 1998-10-06 | Lion Corp | Tacky adhesive composition and poultice |
| JPH10298066A (en) * | 1997-04-24 | 1998-11-10 | Taisho Pharmaceut Co Ltd | Hot patch |
| JPH111428A (en) * | 1997-06-10 | 1999-01-06 | Ooshin Seiyaku Kk | Warmth-giving cataplasm sheet |
| JPH1129434A (en) * | 1997-07-09 | 1999-02-02 | Kao Corp | Sheet-like pack cosmetic |
| JPH11188054A (en) * | 1997-12-25 | 1999-07-13 | Lion Corp | Ex-dermal material |
| JP2000297033A (en) * | 1999-04-14 | 2000-10-24 | Hisamitsu Pharmaceut Co Inc | Cataplasm |
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE45666E1 (en) | 2000-07-07 | 2015-09-08 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
| US8821901B2 (en) | 2001-05-01 | 2014-09-02 | A.V. Topchiev Institute Of Petrochemical Synthesis Russian Academy Of Sciences | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
| US9532935B2 (en) | 2001-05-01 | 2017-01-03 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
| US10869947B2 (en) | 2001-05-01 | 2020-12-22 | Corium, Inc. | Hydrogel compositions |
| US8273405B2 (en) | 2001-05-01 | 2012-09-25 | A.V. Topcheiv Institute of Petrochemical Synthesis, Russian Academy of Sciences | Water-absorbent adhesive compositions and associated methods of manufacture and use |
| US8481071B2 (en) | 2001-05-01 | 2013-07-09 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
| US8481059B2 (en) | 2001-05-01 | 2013-07-09 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Hydrogel compositions |
| US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
| US10835454B2 (en) | 2001-05-01 | 2020-11-17 | Corium, Inc. | Hydrogel compositions with an erodible backing member |
| US8617647B2 (en) | 2001-05-01 | 2013-12-31 | A.V. Topchiev Institutes of Petrochemical Synthesis, Russian Academy of Sciences | Water-absorbent adhesive compositions and associated methods of manufacture and use |
| US10179096B2 (en) | 2001-05-01 | 2019-01-15 | Corium International, Inc. | Hydrogel compositions for tooth whitening |
| US8728445B2 (en) | 2001-05-01 | 2014-05-20 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Hydrogel Compositions |
| US8741331B2 (en) | 2001-05-01 | 2014-06-03 | A. V. Topchiev Institute of Petrochemicals Synthesis, Russian Academy of Sciences | Hydrogel compositions with an erodible backing member |
| US9687428B2 (en) | 2001-05-01 | 2017-06-27 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
| US9089481B2 (en) | 2001-05-01 | 2015-07-28 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
| US9259504B2 (en) | 2001-05-01 | 2016-02-16 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Non-electrically conductive hydrogel composition |
| US9084723B2 (en) | 2001-05-01 | 2015-07-21 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions with an erodible backing member |
| US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
| US9127140B2 (en) | 2001-05-01 | 2015-09-08 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Water-absorbent adhesive compositions and associated methods of manufacture and use |
| JP2005516991A (en) * | 2002-02-01 | 2005-06-09 | ミセル・プロダクツ・インコーポレイテッド | Β-carotene clear micellar formulation for treatment of leukoplakia |
| US9144552B2 (en) | 2004-01-30 | 2015-09-29 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Rapidly dissolving film for delivery of an active agent |
| US8658201B2 (en) | 2004-01-30 | 2014-02-25 | Corium International, Inc. | Rapidly dissolving film for delivery of an active agent |
| JP2008508954A (en) * | 2004-08-05 | 2008-03-27 | コリウム インターナショナル， インコーポレイテッド | Adhesive composition |
| US9242021B2 (en) | 2004-08-05 | 2016-01-26 | Corium International, Inc. | Adhesive composition |
| JPWO2009154086A1 (en) * | 2008-06-17 | 2011-11-24 | 住友精化株式会社 | Acrylate-based water-soluble polymer and gelling base |
| US9610253B2 (en) | 2009-01-14 | 2017-04-04 | Corium International, Inc. | Transdermal administration of tamsulosin |
| US8784879B2 (en) | 2009-01-14 | 2014-07-22 | Corium International, Inc. | Transdermal administration of tamsulosin |
| US10238612B2 (en) | 2009-01-14 | 2019-03-26 | Corium International, Inc. | Transdermal administration of tamsulosin |
| JP2012102083A (en) * | 2010-10-12 | 2012-05-31 | Lion Corp | Skin disease therapeutic agent |
| JP2013231021A (en) * | 2012-05-01 | 2013-11-14 | Jem International Inc | Plaster |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4399044B2 (en) | Absorption enhancer and transdermal absorption preparation comprising the absorption enhancer | |
| US20080138390A1 (en) | Transdermal Delivery System For Use With Basic Permeation Enhancers | |
| HU221166B1 (en) | Transdermal therapeutic system containing estradiol and process for producing the same | |
| JP2001213768A (en) | Poultice | |
| JP2003137773A (en) | Patch having laminated support | |
| JP4199485B2 (en) | Patch | |
| JP2009173679A (en) | Transdermal therapeutic system for administration of partial dopamine-d2 agonist | |
| JP5656221B2 (en) | Transdermal absorption enhancer and transdermal administration preparation using the same | |
| EP3744321B1 (en) | Patch | |
| JPH0429927A (en) | Plaster | |
| JP2007204393A (en) | Skin plaster | |
| WO2020158879A1 (en) | Adhesive patch | |
| JPH05271056A (en) | Controlled powdery agent for transcutaneous administration | |
| WO2006090824A1 (en) | Gel composition and method for producing same | |
| JPH0413617A (en) | Patch | |
| JP2004256396A (en) | Lowly skin-irritating plaster | |
| JP3199770B2 (en) | Patch for transdermal administration and method for producing the same | |
| JPH06256173A (en) | Medical application agent | |
| JPH0798743B2 (en) | Patch | |
| WO1998046267A1 (en) | Base composition for percutaneous absorption and percutaneously absorbable preparation containing the base composition | |
| JPH111441A (en) | Base for percutaneous absorption and percutaneously absorbable preparation containing the same | |
| JP6963663B2 (en) | Manufacturing method of patch | |
| JPH078784B2 (en) | Hydrophilic transdermal preparation | |
| JPH05186371A (en) | Percutaneous absorption preparation | |
| JPH081679U (en) | Skin and transdermal patches having a discontinuous pattern of adhesive layer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070129 |
|
| A621 | Written request for application examination |
Effective date: 20070129 Free format text: JAPANESE INTERMEDIATE CODE: A621 |
|
| RD02 | Notification of acceptance of power of attorney |
Effective date: 20070129 Free format text: JAPANESE INTERMEDIATE CODE: A7422 |
|
| A977 | Report on retrieval |
Effective date: 20100520 Free format text: JAPANESE INTERMEDIATE CODE: A971007 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100601 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101019 |